VIOLET Pharmaceuticals is a preclinical stage biopharma company developing a First-in-Class mRNA therapy against metastatic cancers. The company develops nanotherapies improving immunotherapies’ efficiency and approved indications (e.g. Immune Checkpoints Inhibitors (ICI)) by increasing the whole Antigen Presentation Machinery (APM) in tumor cells. Our mRNA technology is backed by Top-Notch science published in leading journals such as Nature Cell Biology and Nature Cancer, and has a strong IP position (3 patents). We achieved radical complete responses with our mRNA NanoTherapy in combination with ICI in several breast cancer tumors and metastasis models. 
Our mRNA specifically modulates the whole Antigen Presentation Machinery which determines immune detection (tumor visibility) and immunotherapy response. There are currently no specific APM-modulating therapies on the market, only competitors with indirect APM modulation. Therefore, our patented mRNA therapy emerges as a critical therapeutic partner to make tumor cells visible and vulnerable to immunotherapies.
      
VIOLET Pharmaceuticals : Visibility to Immuno-Oncology & Lymphocyte Enhancing Therapies

VIOLET Pharmaceuticals

Org chart

Teams

Offices